Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human BRCA1 Antibodies:
anti-Mouse (Murine) BRCA1 Antibodies:
anti-Rat (Rattus) BRCA1 Antibodies:
Go to our pre-filtered search.
Human Monoclonal BRCA1 Primary Antibody for ChIP, ICC - ABIN450350
Arizti, Fang, Park, Yin, Solomon, Ouchi, Aaronson, Lee: Tumor suppressor p53 is required to modulate BRCA1 expression. in Molecular and cellular biology 2000
Show all 9 Pubmed References
Human Monoclonal BRCA1 Primary Antibody for IHC (p), IP - ABIN445490
Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001
Show all 8 Pubmed References
Human Polyclonal BRCA1 Primary Antibody for FACS, WB - ABIN151683
Zaugg, Su, Reilly, Moolani, Cheung, Hakem, Hirao, Liu, Elledge, Mak: Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. in Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 7 Pubmed References
Human BRCA1 Primary Antibody for IHC - ABIN965694
Kim, Xu, Kastan: Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. in Genes & development 2002
Show all 5 Pubmed References
Human Polyclonal BRCA1 Primary Antibody for IHC - ABIN965696
Arlt, Xu, Durkin, Casper, Kastan, Glover: BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. in Molecular and cellular biology 2004
Show all 5 Pubmed References
Human Monoclonal BRCA1 Primary Antibody for CyTOF, FACS - ABIN152030
Okada, Ouchi: Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. in The Journal of biological chemistry 2003
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody for ICC, FACS - ABIN152032
Martin, Nahas, Tunuguntla, Fike, Gatti: Assessing 'radiosensitivity' with kinetic profiles of γ-H2AX, 53BP1 and BRCA1 foci. in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011
Show all 4 Pubmed References
Polyclonal BRCA1 Primary Antibody for IF - ABIN4948304
Scully, Livingston: In search of the tumour-suppressor functions of BRCA1 and BRCA2. in Nature 2000
Show all 3 Pubmed References
Human Monoclonal BRCA1 Primary Antibody for ChIP, ICC - ABIN151868
Li, Ting, Zheng, Chen, Ziv, Shiloh, Lee, Lee: Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. in Nature 2000
Show all 3 Pubmed References
Human Polyclonal BRCA1 Primary Antibody for IP, PLA - ABIN151492
Rusin, Zajkowicz, Butkiewicz: Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. in Mechanisms of ageing and development 2009
Show all 2 Pubmed References
Risk-reducing bilateral salpingo-oophorectomy is currently the most effective method for reducing the risk of ovarian cancer in BRCA mutation (BRCA1 and BRCA2 (show BRCA2 Antibodies)) carriers.
miR (show MLXIP Antibodies)-151-5p, targeting chromatin remodeler SMARCA5 (show SMARCA5 Antibodies), may act as a useful biomarker for BRCA-related and sporadic breast cancers.
Our data suggest that in both BRCA1-mutant and BRCA1-wild-type TNBCs, CSCs are relatively resistant to PARP (show COL11A2 Antibodies) inhibition. This resistance is mediated by RAD51 (show RAD51 Antibodies), suggesting that strategies aimed at targeting RAD51 (show RAD51 Antibodies) may increase the therapeutic efficacy of PARPi
We examined the intratumor variability of BRCA1/2 mutation, BRCA1 promoter methylation status, and the overall HRD score in small samples from different areas of the same cancer. We observed highly concordant HRD scores across different regions of the same cancer suggesting that HRD, when present, is a homogeneous feature of primary breast cancers
As BRCA1-mutated ER(+) tumors show a BRCAness copy number profile and LOH, it is likely that the loss of a functional BRCA1 protein plays a role in tumorigenesis in BRCA1-mutated ER(+) tumors. Therefore, we hypothesize that these tumors are sensitive to drugs targeting the BRCA1 gene defect, providing new targeted treatment modalities for advanced BRCA-deficient, ER(+) breast cancer
Hypermethylation in BRCA1 is associated with earlier occurrence of ovarian cancer.
Three new isogenic ovarian cancer cell lines were developed from a patient with a germ line BRCA1 mutation.
Patientswith BRCA1/2 mutation had longer OS than thosewith BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.
Women with the BRCA1 mutation had a significant decline in AMH (show AMH Antibodies) with age (p = 0.0011). BRCA1-positive women >35 years had 10 times the odds of a low AMH (show AMH Antibodies) (<0.5 ng/mL) compared with women =35 years.
Study suggests that BRCA1 p.Arg762Ser is likely to be associated with breast cancer risk in Malaysian population.
Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.
The gene-specific SNP marker analysis showed a significant association of BRCA1 C28300A with milk somatic cell scores.
In general, OC use, childbearing and breastfeeding do not differ between BRCA1/2 carriers and non-carriers with ovarian cancer. However, the effects of tubal ligation may differ between BRCA1 carriers and non-carriers.
Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents.These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress.
Consensus-based recombinant adeno-associated virus-BRCA1 knock out virus vectors failed to induce BRCA1 knockout in Gottingen fibroblasts.
Brca1 is necessary for hematopoietic stem cells maintenance and normal hematopoiesis and that distinct mutations lead to different degrees of hematopoietic dysfunction.
TGFbeta (show TGFB1 Antibodies) stabilized the abundance of BRCA1 by reducing the abundance of microRNA-182 (miR (show MLXIP Antibodies)-182). Ectopic expression of BRCA1 or antagonism of miR (show MLXIP Antibodies)-182 in cultured TGFbeta (show TGFB1 Antibodies)-deficient mammary epithelial cells restored luminal lineage commitment.
BRCA1 inactivation can increase expression of miR (show MLXIP Antibodies)-155, contributing to cardiac hypertrophy. And Rev produces their beneficial effects partially by down-regulating miR (show MLXIP Antibodies)-155 expression, which might be a novel strategy for treatment of cardiac hypertrophy.
both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells express a new gene domain-less (RING-less) BRCA1 protein that mediated resistance to homologous recombination deficient-targeted therapies
Genomic instability can be rescued by deletion of Trp53bp1 (show TP53BP1 Antibodies), encoding the DNA damage response factor 53BP1 (show TP53BP1 Antibodies); mice expressing RING-less BRCA1 do not show an increased susceptibility to tumors in the absence of 53BP1 (show TP53BP1 Antibodies); Genomic instability in cells expressing RING-less BRCA1 correlates with loss of BARD1 (show BARD1 Antibodies) and a defect in restart of replication forks after hydroxyurea treatment
the aberrant proliferative capacity of Brca1(-/-) luminal progenitor cells is linked to the replication-associated DNA damage response, where proliferation of mammary progenitors is perpetuated by damage-induced, autologous NF-kappaB (show NFKB1 Antibodies) signaling.
We report here elevated recombination rates at telomeres in cells from human BRCA1 mutation carriers and in mouse embryonic stem cells lacking both copies of functional Brca1.
loss of Brca1, a tumor suppressor that functions in DNA damage repair, in the mammary epithelium induced senescence with induction of p16 (show CDKN2A Antibodies) and a decline of stem cell function, which was rescued by p16 (show CDKN2A Antibodies) loss.
Brca1-Wwox (show WWOX Antibodies) interaction supports non-homologous end-joining as the dominant DSB repair pathway in Wwox (show WWOX Antibodies)-sufficient cells
Structure-guided separation-of-function mutations show that the RNF8 E2 stimulating activity is essential for DSB signaling in mammalian cells and is necessary for downstream recruitment of 53BP1 and BRCA1.
MRN (Mre11 (show MRE11A Antibodies), Rad50 (show RAD50 Antibodies), and Nbs1 (show NLRP2 Antibodies)) complex, CtIP (show RBBP8 Antibodies), and BRCA1 are required for both the removal of Top2 (show TOP2 Antibodies)-DNA adducts and the subsequent resection of Top2 (show TOP2 Antibodies)-adducted DSB ends.
BRCA1-dependent helicase (show DNA2 Antibodies) unloading is a critical, early event in DNA interstrand crosslink repair.
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.
BRCA1/BRCA2-containing complex, subunit 1
, RING finger protein 53
, breast and ovarian cancer susceptibility protein 1
, breast and ovarian cancer sususceptibility protein 1
, breast cancer type 1 susceptibility protein
, protein phosphatase 1, regulatory subunit 53
, BRCA1 homologue
, breast cancer type 1 susceptibility protein homolog
, breast cancer 1, early onset
, BRCA1 homolog
, breast and ovarian cancer susceptibility protein
, breast cancer associated 1